Beta thalassemia is a rare inherited blood disorder disease that reduces haemoglobin production in a human body. The iron containing protein in RBC (red blood cell), haemoglobin carries oxygen throughout the body. Low content of haemoglobin due to absences of synthesis of beta chains of haemoglobin leads to low oxygen carrying capacity of blood cells. As a result, the outcome varies from severe anemia to clinically asymptomatic depending upon the nature of mutations in HBB (Haemoglobin, Beta) gene or the chromosomes.
Based on the severity observed in symptoms, the diseases is classified into three, thalassemia minor, thalassemia intermediate and thalassemia major (also known as Cooley’s anemia). Among these, thalassemia major is signified as the most severe. Diagnostic tests pertaining to beta thalassemia CBC (Complete blood count) determines RBC and amount of haemoglobin in a blood sample. DNA testing is also another significant diagnostic approach to detect mutation in HBB gene that may results alpha, beta or delta thalassemia. It also provides verification and confirmation in other tests like blood test. Other tests such as prenatal genetic testing thalassemia, CVS (Chorionic villus sampling) and PGD (Pre-implantation genetic diagnosis) are performed on fetus or embryos in in-vitro fertilization to detect carrier of mutated thalassemia genes.
Increasing advancement in medical technology along with increasing incidences of genetic disorders such as severe anaemia and sickle cell diseases is highly likely to support production of beta thalassemia testing systems. Thereby, several manufacturing companies in global beta thalassemia testing market are investing heavily in research & development activities in order to introduce innovative technologies in their existing product portfolio and services. Moreover, key market players are profoundly participating in potential mergers and acquisitions in order to strengthen market position at domestic as well as global platform in coming years.
Sanofi to Acquire Bioverativ for US$ 11.6 Bn
A multinational pharmaceutical company based in France, Sanofi S. A. has announced to acquire the American multinational biotechnology company, Bioverative for approximately US$ 11.6 Bn. The company focuses to expand the product portfolio in specialty care and rare disease presence segments. Moreover Bioverative focuses in development of therapies for hemophilia and rare blood disorders. Such acquisition is highly likely to help Sanofi to leverage clinical expertise of Bioverativ and its existing commercial platform in order to advance RNAi (RNA interference), an investigational therapeutics for hemophilia A and B. furthermore, Bioverativ product portfolio includes phase-III testing for cold agglutinin coupled with early stage research program and collaboration in hemophilia and rare blood diseases such as beta thalassemia and sickle cells.
Request Report Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-1738